Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 5
Submit an article Journal homepage
30
Views
18
CrossRef citations to date
0
Altmetric
Review

Antiretroviral therapy and mother-to-child transmission of HIV-1

Marie-Louise Newell University College London, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. [email protected]
&
Claire Thorne University College London, Centre for Paediatric Epidemiology and Biostatistics, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. [email protected]
Pages 717-732 | Published online: 10 Jan 2014

References

  • UNAIDS. Implementing the declaration of commitment on HIV/AIDS. Action guide for United Nations Country Teams. UNAIDS, Geneva, Switzerland (2002).
  • Breastfeeding and HIV International Transmission Study (BHITS). Late postnatal transmission of HIV-1 through breastfeeding: an individual patient data meta-analysis. J. Infect. Dis. 189, 2154–2166 (2004).
  • European Collaborative Study. Vertical transmission of HIV-1: maternal immune status and obstetric factors. AIDS10, 1675–1681 (1996).
  • Kumar RI, Uduman SA, Khurranna AK. A prospective study of mother-to-infant HIV transmission in tribal women from India. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 9,238–242 (1995).
  • Working Group on Mother-to-Child Transmission of HIV. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results from 13 perinatal studies. J. Acquir. Immune Defic. Syndr. Hum. RetroviroL 8,506–510 (1995).
  • Matheson PB, Thomas PA, Abrams EJ, et al. Heterosexual behavious during pregnancy and perinatal transmission of HIV-1. AIDS 10, 1249–1256 (1996).
  • Dabis F, Msellati P, Dunn DT, et al. Estimating the rate of mother-to-child transmission of HIV. Report of a workshop on methodological issues, Ghent (Belgium), 17–20 February 1992. AIDS 7, 1139–1148 (1993).
  • Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N EngL J. Med. 327, 1246–1247 (1992).
  • Newell ML. Mechanisms and timing of mother-to-child transmission of HIV-1. AIDS 12,831–837 (1998).
  • Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS 13,407–414 (1999).
  • de Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV Transmission in resource-poor countries — translating research into policy and practice. J. Am. Med. Assoc. 283(9), 1175–1182 (2000).
  • Van Dyke RB, Korber BT, Popek EJ, et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus Type 1 in the era of maternal antiretroviral therapy. J. Infect. Dis. 179,319–328 (1999).
  • Nduati RW, John GC, Ngacha DA, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. J. Am. Med. Assoc. 283(9), 1167–1174 (2000).
  • Richardson BA, John-Stewart GC, Hughes JP, et al. Breast milk infectivity in human immunodeficiency virus Type 1-infected mothers. J. Infect. Dis. 187,736–740 (2003).
  • John-Stewart GC, Mbori-Ngacha D, Ekpini ER, et al. Breast-feeding and transmission of HIV-1. J. Acquir. Immune Defic. Syndr. Hum. RetroviroL 35,196–202 (2004).
  • Saez-Llorens X, Violari A, Deetz CO, et al. 48 week evaluation of lopinavir/ritonavir, a new protease inhibitor, in HIV infected children. Pediatr. Infect. Dis. J. 22,216–223 (2003).
  • Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus Type 1 RNA and the risk of perinatal transmission. N EngL J. Med. 341, 394–402 (1999).
  • Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 353, 773–780 (1999).
  • Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J. Acquir. Immune Defic. Syndr. Hum. RetroviroL 29,484–494 (2002).
  • Ioannidis JPA, Abrams EJ, Bulterys M, et al. Perinatal transission of human immunodeficiency virus Type 1 by pregnant women with RNA virus loads copies/ml. J. Infect. Dis. 183, 539–545 (2001).
  • Chuachoowong R, Shaffer N, Siriwasin W, et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus Type 1 RNA levels and risk of perinatal transmission. J. Infect. Dis. 181,99–106 (2000).
  • Tuomala RE, °Driscoll PT, Bremer JW, et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus Type 1 in antiretroviral-experienced women. J. Infect. Dis. 187(3), 375–384 (2003).
  • John GC, Nduati RW, Mbori-Ngacha D, et al. Correlates of mother-to-child human immunodeficiency virus Type 1 (HIV-1) transmission: association with maternal plasma HIV-1 RNA load, genital HIV-1 DNA shedding and breast infections. J. Infect. Dis. 183,206–212 (2001).
  • Seck K, Samb N, Tempesta S, et al. Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal. Sex Transm. Infect. 77(3), 190–193 (2001).
  • European Collaborative Study. Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. AIDS 13,1377–1385 (1999).
  • Ioannidis JPA, Tatsioni A, Abrams EJ, et al. Maternal viral load and rate of disease progression among vertically HIV-1 infected children: an international meta-analysis. AIDS 18,99–108 (2004).
  • The International Perinatal HIV group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. AIDS 15,357–368 (2001).
  • Fawzi WW, Msamanga GI, Renjifo B, et al. Predictors of intrauterine and intrapartum transmission of HIV-1 among Tanzanian women. AIDS 15,1157–1165 (2001).
  • Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N EngL J. Med. 344,720–725 (2001).
  • Willumsen JF, Newell ML, Filteau SM, et al. Variation in breastmilk HIV-1 viral load in left and right breasts during the first 3 months of lactation. AIDS 15(14), 1896–1897 (2001).
  • Willumsen JF, Filteau SM, Coutsoudis A, et al. Breastmilk RNA viral load in HIV-infected South African women: effects of subdinical mastitis and infant feeding. AIDS 17,407–414 (2003).
  • Rousseau CM, Nduati RW, Richardson BA, et al. Longitudinal analysis of human immunodeficiency virus Type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J. Infect. Dis. 187,741–747 (2003).
  • •Provides a comprehensive description of fluctuations in breast milk viral load in HIV-infected women throughout the breastfeeding period, and how this relates to postnatal transmission of the virus.
  • Coutsoudis A, Pillay K, Kuhn L, et al. Methods of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS is, 379–387 (2001).
  • Rollins N, Meda N, Becquet R, et al. Preventing postnatal transmisssion of HIV-1 through breast-feeding: modifying infant feeding practices. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 35, 188–195 (2004).
  • World Health Organization. HIV transmission through breastfeeding. A review of available evidence. WHO, Geneva, Switzerland (2004).
  • Connor EM, Sperling RS, Gelber RD, et al. Reduction of maternal-infant transmission of human immunodeficiency virus Type 1 with zidovudine treatment. N. Eng. J. Med. 331,1173–1180 (1994).
  • European Collaborative Study. Are girls more at risk of intrauterine-acquired HIV infection than boys? AIDS 18,344–347 (2004).
  • The European Mode of Delivery Collaboration. Elective cesarean section versus vaginal delivery in preventing vertical HIV-1 transmission: a randomized clinical trial. Lancet 353, 1035–1039 (1999).
  • The International Perinatal HIV group. Mode of delivery and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies. N Engl J. Med. 340(13), 977–987 (1999).
  • Rowland BL, Vermillion ST, Soper DE. Scheduled cesarean delivery and the prevention of human immunodeficiency virus transmission: a survey of practicing obstetricians. Am. J. Obstet. Gynecol 185(2), 327–331 (2001).
  • US Public Health Service Task Force. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention, NJ, USA (2002).
  • Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission. A randomized trial. J. Am. Med. Assoc. 288,189–198 (2002).
  • Cooper ER, Charurat M, Burns DN, et al. Trends in antiretroviral therapy and mother-infant transmission of HIV. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 24,45–47 (2000).
  • •Results from an observational study, including information on the rates of mother-to-child transmission (MTCT) among women receiving highly active antiretroviral therapy (HAART).
  • Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidouvudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J. Med. 351(3), 217–228 (2004).
  • •Results from an important trial looking at boosting traditional short-course antiretroviral therapy (ART) prophylaxis with peripartum nevirapine (maternal and infant dose) in a nonbreastfeeding population.
  • Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomized clinical trial. Lancet 362, 1171–1177 (2003).
  • Mirochnick M, Dorenbaum A, Blanchard S, et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 33(2), 153–156 (2003).
  • Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann. NY Acad. Sci. 918, 287–297 (2000).
  • Mandelbrot L, Peytavin G, Firtion G, Farinotti R. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am. J. Obstet. Gynecol 184,153–158 (2001).
  • Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passage of protease inhibitors at delivery. AIDS 16,889–893 (2002).
  • Vitayasai V, Moyle G, Supajatura V, et al. Safety and effiacy of saquinavir soft-gelatin capsules and zidovudine and optional lamivudine in pregnancy and the prevention of vertical HIV transmission. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 30(4), 410–412 (2002).
  • European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 15,761–770 (2001).
  • European Collaborative Study. Pregnancy-related changes in the longer-term management of HIV infected women in Europe. Eur. J. Obstet. Gynecol Rep rod. Biol. 11, 3–8 (2003).
  • Watts DH, Balasubramanian R, Maupin RT, et al. Maternal toxicity and pregnancy complications in HIV-infected women receiving antiretroviral therapy: an analysis of the PACTG 316 Study. Am. J. Obstet. Gynecol 190, 506–516 (2004).
  • •Results from this analysis of data on women enrolled in the Pediatric AIDS Clinical Trial Group (PACTG) 316 trial includes the finding of an increased risk of gestational diabetes associated with protease inhibitor (PI)-containing HAART.
  • The Italian Register for HIV Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the introduction of zidovudine prophylaxis. Arch. Pediatr. Adolesc. Med. 156(9), 915–921 (2002).
  • European Collaborative Study and the Swiss Mother+Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 14, 2913–2920 (2000).
  • •Combined analysis from two observational cohort studies showing a strong association between combination therapy use in pregnancy and prematurity.
  • European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 32,380–387 (2003).
  • •Large cohort study presenting important information on lack of serious clinical adverse effects of exposure to ART among uninfected children in the short to medium term.
  • European Collaborative Study. Pregnancy outcome in ART-treated HIV-infected women in Europe. Proceedings and Abstracts of the 11th Conference on Retroviruses and Opportunitistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 98).
  • Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J. Med. 346(24), 1863–1870 (2002).
  • Fiore S, Newell ML, Trabattoni D, et al. Pregnancy, HIV infection and immune responses. Proceedings and Abstracts of the XIV International AIDS Conference. Barcelona, Spain, 7–12 July 2002 (Abstract A10109).
  • Coll O, Suy A, Martinez E, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretrovial therapy. Proceedings and Abstracts of the 11th Conference on Retroviruses and Opportunitistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 921).
  • Jungmann EM, Mercey D, DeRuiter A, et al. Is the first trimester exposure to the combination of antriretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex. Transm. Infect. 77,441–443 (2001).
  • Chmait R, Franklin P, Spector SA, Hull AD. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J. Perinatal 22,370–373 (2002).
  • Kramer F, Stek AM, Kovacs AAS, Du WB. Nevirapine tolerability in HIV-infected women in pregnancy. Proceedings and Abstracts of the 1 1 th Conference on Retroviruses and Opportunitistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 923).
  • Lyons F, Hopkins S, McGeary A, et al. Nevirapine tolerability in HIV infected women in pregnancy — a word of caution. Proceedings and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13 July 2003 (Abstract LB27).
  • •Includes the case reports of two cases of fatal fulminant hepatitis associated with nevirapine use in pregnancy.
  • Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 36(3), 772–776 (2004).
  • Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex. Transm. Infect. 78,58–59 (2002).
  • Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analog-induced lactic acidosis in the third trimester of pregnancy. AIDS 17,272–273 (2003).
  • Taha TE, Kumwenda NI, Gibbons A, et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS 16(6), 851–858 (2002).
  • Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S. Perinatal antiretroviral treatment and hematopoiesis in HIV — uninfected infants. AIDS 17(14), 2053–2061 (2003).
  • Bunders M, Newell ML, European Collaborative Study. Levels and patterns of neutrophil counts in children born to HIV-infected mothers: association with HIV, ART, gender and race. Proceedings and Abstracts of the XV International AIDS Conference. Bangkok, Thailand, 11–16 July 2004 (Abstract ThPeB7013).
  • Tohzis P, Marz CM, Kleinman N, Levine EM, Schmidt EV. Zidovudine-associated embryonic toxicity in mice. J. Infect. Dis. 163,1212–1218 (1991).
  • Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacental genotoxicity in combined antiretroviral nucleoside therapy in Erythrocebus patas monkeys. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 29(4), 323–329 (2002).
  • Olivero OA, Shearer GM, Chouquet CA, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1 positive adults and pregnant women and cord blood from infants exposed in utero. AIDS 13,919–925 (1999).
  • Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. AIDS 30(2), 200–215 (2002).
  • Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. J. Am. Med. Assoc. 13(2), 151–157 (1999).
  • Hanson IC, Antonelli A, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 20,463–467 (1999).
  • Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354, 1084–1089 (1999).
  • French Perinatal Cohort Study. Risk of early febrile seizure with perinatal exposure to nucleoside analogs (article). Lancet 359, 583–584 (2002).
  • Lindegren ML, Rhodes PH, Gordon L, Fleming PL. Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance. Ann. 1VY Acad. Sci. 918,222-235 (2000).
  • Divi RL, Walker V, Wade N, et al. Mitochrondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir®. AIDS 18(5), 1013–1021 (2004).
  • Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 32(4), 370–374 (2003).
  • Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in HIV-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr. Infect. Dis. J. 22(9), 782–789 (2003).
  • Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus Type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J. Infect. Dis. 186, 181–188 (2002).
  • Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 30,216–229 (2002).
  • Ekpini ER, Nkenganson J, Sibailly TS, et al. Changes in plasma HIV-1 RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 16,625–630 (2002).
  • Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15,1951–1957 (2001).
  • Jourdain G, Ngo-Giang Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J. Med 351,229–240 (2004).
  • Mandelbrot L, Landreau A, Rekacewicz C, et al. Lamivudine—zidovudine combination for prevention of maternal-infant transmission of HIV-1. J. Am. Med. Assoc. 285(16), 2083–2093 (2001).
  • Johnson VA, Petropoulos CJ, Woods CR, et al. Vertical transmission of multidrug-resistant human immunodeficiency virus Type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1 infected infant. J. Infect. Dis. 183,1688–1693 (2001).
  • Hirsch MS, Brun-Vezinet F, d'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society — USA Panel. J. Am. Med Assoc. 283(18), 2417–2426 (2000).
  • Newell ML, Rogers MF. Pregnancy and HIV infection: a European consensus on management. AIDS 16, S1—S18 (2002).
  • WHO/UNICEF/UNAIDS. New data on the prevention of mother-to-child transmission of HIV and their policy 108 Parker MM, Wade N, Lloyd RM Jr, et al. among a cohort of HIV-infected newborns. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 32,292-297 (2003). implications: conclusions and recommendations. WHO, Geneva, Switzerland (2000).
  • Department of Nutrition for Health and Development, Department of Child and Adolescent Health and Development. Report of the Expert Consultation on the optimal duration of exclusive breastfeeding, 28–30 March 2001. World Health Organization, Geneva, Switzerland. 1–10 (2002).
  • Gaillard P, Fowler MG, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breastfeeding: from animal studies to randomized clinical trials. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol 35,178–187 (2004).
  • Vyankandondera J, Luchters S, Hassink E, et al. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA). Proceedings and Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13 July 2003 (Abstract LB7).
  • •Preliminary results from the first trial to investigate ART to prevent postnatal transmission of HIV. Numbers are small and follow-up period limited; data collection on breastfeeding modalities is not extensive. Follow-up is still continuing.
  • The French Pediatric HIV Infection Study Group, European Collaborative Study. Morbidity and mortality in European children vertically infected by HIV-1. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14,442–450 (1997).
  • de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. J. Am. Med. Assoc. 284,190–197 (2000).
  • Diaz C, Hanson C, Cooper ER, et al. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth: the women and infants transmission study (WITS). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18,221–228 (1998).
  • Bernardi S, Thorne C, Newell ML, et al. Variable use of therapeutic interventions for HIV-infected children in Europe. Eur. J. Pediatr. 159,170–175 (2000).
  • Junghans C, Low N, Chan PS, et al. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 13(18), 2547–2554 (1999).
  • Funk MB, Linde RD, Braner HJ, et al. Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in HIV-infected children. Eur. J. Pediatr. 158,86–87 (1999).
  • Resino S, Bellon JM, Resino R, et al. Extensive Implementation of Highly Active Antiretroviral Therapy shows great effect on survival and sarrogate markers in vertically HIV-infected children. Clin. Infect. Dis. 38(11), 1605–1612 (2004).
  • European Collaborative Study. Management of vertically HIV-infected children in Europe. Acta Paediatr. 92, 246–250 (2003).
  • Gortmaker SL, Hughes MD, Cervia JS, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolecents infected with HIV-1. N Engl J. Med. 345(21), 1522–1528 (2001).
  • Paediatric European Network for Treatment of AIDS (PENTA). Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 18(2), 237–245 (2004).
  • Luzuriaga K, McManus M, Mofenson LM, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J. Med. 350,2471–2480 (2004).
  • Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analog reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treates: the PENTA 5 randomized trial. Lancet 359(9308), 733–740 (2002).
  • Eshlemann SH, Krogstad P, Jackson JB, et al. Analysis of HIV-1 drug resistance in children receiving nucleoside analog reverse-transcriptase inhibitors plus nevirapine, nelfinavir or ritonavir (Pediatric AIDS Clinical Trials Group 377)1. Infect. Dis. 183,1732-1738 (2001).
  • The Euro Guidelines Group for HIV resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15,309–320 (2001).
  • Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1 infected children on antiretrovirals (letter). Lancet 353(9160), 1243–1244 (1999).
  • Jaquet D, Levine MM, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14(14), 2123–2128 (2000).
  • Arpadi SM, Cuff PA, Horlick MN, Wang J, Kotler DP Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ lymphocyte count and CD4+ lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir. Immune Defic. Syndr Hum. Retrovirol 27, 30–34 (2001).
  • Vigano A, Mora S, Testolin C, et al. Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children. J. Acquir. Immune Defic. Syndr Hum. Retrovirol 32, 482–489 (2003).
  • Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 17(9), 1319–1327 (2003).
  • European Paediatric Lipodystrophy Group. Antiretroviral therapy, Et redistribution and dyslipidemia in HIV-infected children in Europe. AIDS 18,1443–1451 (2004).
  • •Large cross-sectional study of the prevalence and risk factors for fat redistribution in infected children on ART.
  • McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 111(3), E275—E281 (2003).
  • Mora S, Sala N, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 15,1823–1829 (2001).
  • Tan BM, Nelson RP, James-Yarish M, Emmanuel PJ, Svhurman SJ. Bone metabolism in children wuth HIV infection receiving highly active antiretroviral theraphy including a protease inhibitor. J. Pediatr 139(3), 447–451 (2001).
  • Vigano A, Zamproni I, Giacomet V, et al. Analysis of bone mineral content in antiretroviral-naive and highly active antiretroviral-treated HIV-infected children. Proceedings and Abstracts of the 11th Confirence on Retroviruses and Opportunitistic Infections. San Francisco, CA, USA, 8–11 February 2004 (Abstract 943).
  • Noguera A, Fortuny C, Sanchez E, et al. Hyperlactatemia in HIV infected children receiving antiretroviral treatment. Pediatr. Infect. Dis. J. 22,778–782 (2003).
  • Wiktor SZ, Ekpini ER, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomized trial. Lancet 353,781–785 (1999).
  • Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicenter trial. Lancet 353,786–792 (1999).
  • Dabis F, Elenga N, Meda N, et al. 18-month mortality and perinatal exposure to zidovudine in west Africa. AIDS 15(6), 771–779 (2001).
  • Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of HIV-1. N EngL J. Med. 343,982–991 (2001).
  • The Petra study team. Efficacy of the three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa and Uganda (Petra study): a randomized, double-blind, placebo-controlled trial. Lancet 359, 1178–1186 (2002).
  • Chaisilwattana P, Chokephaibulkit K, Chalermchokcharoenkit A, et al. Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus Type 1 in Thailand. Clin. Infect. Dis. 35(11), 1405–1413 (2002).
  • Guay LA, Musoke P, Fleming TR, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 354,795–802 (1999).
  • Moodley D, Moodley J, Coovadia HM, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus Type 1. J. Infect. Dis. 187,725–735 (2003).
  • •Presents results from a trial that confirm the efficacy and safety of short-course ART regimens in reducing MTCT risk in developing countries.
  • Dabis F, Ekouevi DK, Merchadou L, et al. Effectiveness of a short course of ZDV plus 3TC boosted peripartum by nevirapine to prevent HIV-1 mother-to-child transmission. 13th International Confirence on AIDS and Sexually Transmitted Infictions in Africa. Nairobi, Kenya, 21–26 September 2003.
  • Dabis F, Ekouevi DK, Bequet L, et al. A short course of Zidovudine + peripartum nevirapine is higly efficious in preventing mother-to-child transmission of HIV-1: The ANRS 1201 ditrame-plus group. The 10th Confirence on Retroviruses and Opportunistic Infictions. Boston, MA, USA, 10–14 February 2003 (Poster 854).

Websites

  • •Preliminary results from an important trial looking at boosting traditional short-course ART prophylaxis with peripartum nevirapine (maternal and infant dose) in breastfeeding populations.
  • World Health Organization. AIDS Epidemic Update December 2002. www.unaids.org/worldaidsday/2002/press/Ep iupdate.html (Accessed September 2004)
  • Food and Drug Administration. 2004 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements — Viramune www.fda.gov/medwatch/SAFETY/2004/safet y04.htm#viramune (Accessed September 2004)
  • Food and Drug Administration. Important drug warning — Zerit and Videx. www.fda.gov/medwatch/safety/2001/zerit&vi dex letter.htm 7 (Accessed September 2004)
  • World Health Organization 3 by 5 initiative. www.who.int/3by5 (Accessed September 2004)
  • Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. hivatis.org/trtgdlns.html#perinatal (Accessed September 2004)
  • HIV/AIDS Treatment Information Service website AIDSInfo.nih.org (Accessed September 2004)
  • WHO recommendations for use of ARV prophylaxis for prevention of mother-to-child transmission in resource-constrained settings. www.who.int/hiv/pub/mtct/guidelines/en/ (Accessed September 2004)
  • The Paediatric European Network for Treatment of AIDS (PENTA) guidelines. www.pentatrials.org (Accessed September 2004)
  • The US Department of Health and Human Services guidelines. www.aidsinfo.nih.gov/guidelines (Accessed September 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.